文献速递消化系统肿瘤

表皮生长因子受体的表观遗传与转录调控调节胰腺癌肿瘤免疫微环境

Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
PubMed 文献 · Cancer Discov · 2020-11-06

该研究通过体内CRISPR筛选发现KDM3A是胰腺导管腺癌免疫治疗应答的表观遗传调控因子,KDM3A通过KLF5和SMAD4调控EGFR表达,敲除KDM3A、KLF5、SMAD4或EGFR可改变免疫微环境并使肿瘤对联合免疫治疗敏感,而EGFR抑制剂厄洛替尼可剂量依赖性地增加瘤内T细胞。

要点

  • KDM3A是胰腺癌免疫治疗应答的表观遗传调控因子。
  • KDM3A通过KLF5和SMAD4调控EGFR表达。
  • EGFR抑制剂厄洛替尼可增加瘤内T细胞并增敏免疫治疗。

核心结论

  • 肿瘤细胞通过KDM3A-KLF5-SMAD4-EGFR表观遗传-转录网络调节免疫微环境,EGFR抑制可增敏胰腺癌免疫治疗。

研究设计与样本

  • 研究采用体内CRISPR筛选鉴定胰腺导管腺癌免疫治疗应答的表观遗传调控因子。

主要发现

  • 敲除KDM3A、KLF5、SMAD4或EGFR改变免疫肿瘤微环境并使肿瘤对联合免疫治疗敏感。
  • 厄洛替尼处理已建立肿瘤可剂量依赖性增加瘤内T细胞。

临床怎么用

  • EGFR抑制剂可能作为胰腺癌免疫治疗的增敏策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although immunotherapy has revolutionized cancer care, patients with pancreatic ductal adenocarcinoma (PDA) rarely respond to these treatments, a failure that is attributed to poor infiltration and activation of T cells in the tumor microenvironment (TME). We performed an in vivo CRISPR screen and identified lysine demethylase 3A (KDM3A) as a potent epigenetic regulator of immunotherapy response in PDA. Mechanistically, KDM3A acts through Krueppel-like factor 5 (KLF5) and SMAD family member 4 (SMAD4) to regulate the expression of the epidermal growth factor receptor (EGFR). Ablation of KDM3A, KLF5, SMAD4, or EGFR in tumor cells altered the immune TME and sensitized tumors to combination immunotherapy, whereas treatment of established tumors with an EGFR inhibitor, erlotinib, prompted a dose-dependent increase in intratumoral T cells. This study defines an epigenetic-transcriptional mechanism by which tumor cells modulate their immune microenvironment and highlights the potential of EGFR inhibitors as immunotherapy sensitizers in PDA. SIGNIFICANCE: PDA remains refractory to immunotherapies. Here, we performed an in vivo CRISPR screen and identified an epigenetic-transcriptional network that regulates antitumor immunity by converging on EGFR. Pharmacologic inhibition of EGFR is sufficient to rewire the immune microenvironment. These results offer a readily accessible immunotherapy-sensitizing strategy for PDA.This article is highlighted in the In This Issue feature, p. 521.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Li J, Yuan S, Norgard RJ, et al. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Cancer Discov. 2020. PMID: 33158848. doi:10.1158/2159-8290.CD-20-0519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。